<p>IGM Biosciences, Inc.（纳斯达克代码：IGMS - 获取免费报告）的股票目前被十位分析师一致评定为 “减持”，MarketBeat Ratings 报告称。其中一位股票研究分析师给予该股票 “卖出” 评级，九位分析师则给予该公司 “持有” 评级。在过去一年中更新了对该股票覆盖的分析师中，平均一年目标价为 5.50 美元。</p>
<p>获取 <strong>IGM Biosciences</strong> 的提醒：</p>
<p>另外，华尔街禅在 6 月 7 日的报告中将 IGM Biosciences 的股票评级从 “持有” 下调至 “卖出”。</p>
<p><strong>查看我们最新的 IGM Biosciences 股票分析</strong></p>
<h2>IGM Biosciences 股票表现</h2>
<p>纳斯达克：IGMS 周四开盘价为 1.27 美元。IGM Biosciences 的 52 周低点为 0.92 美元，52 周高点为 22.50 美元。该公司的市值为 7657 万美元，市盈率为-1.41，贝塔值为 0.60。该公司的 50 日简单移动平均线为 1.27 美元，200 日简单移动平均线为 1.28 美元。</p>
<p>IGM Biosciences（纳斯达克：IGMS - 获取免费报告）最近于 7 月 31 日发布了季度财报。该公司报告的季度每股收益为 1.58 美元，超出分析师一致预期的-0.30 美元，差额为 1.88 美元。IGM Biosciences 的股本回报率为-93.35%，净利润率为-36.81%。该公司在本季度的收入为 1.4362 亿美元，而一致预期为 320 万美元。卖方分析师预计 IGM Biosciences 在本年度将发布-3.35 美元的每股收益。</p>
<h2>对 IGM Biosciences 的对冲基金看法</h2>
<p>几家对冲基金最近买入和卖出了 IGMS 的股票。赛诺菲在第四季度新购入了 IGM Biosciences 的股份，价值约 879.2 万美元。Two Sigma Investments LP 在第四季度将其在 IGM Biosciences 的持股增加了 196.7%。Two Sigma Investments LP 目前拥有 107,620 股该公司的股票，价值 65.8 万美元，此前在上一季度又购买了 71,343 股。Geode Capital Management LLC 在第四季度将其在 IGM Biosciences 的持股增加了 3.4%。Geode Capital Management LLC 目前拥有 409,133 股该公司的股票，价值 250.1 万美元，此前在上一季度又购买了 13,334 股。Renaissance Technologies LLC 在第四季度将其在 IGM Biosciences 的持股增加了 14.0%。Renaissance Technologies LLC 目前拥有 75,800 股该公司的股票，价值 46.3 万美元，此前在上一季度又购买了 9,300 股。最后，Susquehanna Fundamental Investments LLC 在第四季度新购入了 IGM Biosciences 的股份，价值约 22.2 万美元。42.79% 的股票由机构投资者持有。</p>
<h2>关于 IGM Biosciences</h2>
<p>（获取免费报告）</p>
<p>IGM Biosciences, Inc.是一家临床阶段的生物技术公司，开发用于治疗癌症以及自身免疫和炎症性疾病的免疫球蛋白 M（IgM）抗体。它开发了 Aplitabart，一种用于治疗结直肠癌的死亡受体 5 激动剂 IgM 抗体；imvotamab，一种 CD20 x CD3 双特异性 IgM 抗体，用于治疗肌炎，以及用于治疗系统性红斑狼疮和类风湿性关节炎，目前处于 Ib 期临床试验；以及 IGM-2644，一种双特异性 T 细胞结合 IgM 抗体，靶向 CD38 和 CD3 蛋白，用于治疗自身免疫疾病。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票比 IGM Biosciences 更好</li>
<li>基础材料股票投资</li>
<li>三份财报提供消费者情绪快照</li>
<li>每股收益计算器：如何计算 EPS</li>
<li>亚马逊的空头已举白旗——值得期待</li>
<li>股票评级和推荐：理解分析师评级</li>
<li>Tempus AI 强劲的第二季度推动增长故事——未来还有更多上升空间？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUdNUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUdNUw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 IGM Biosciences 吗？</h2>
<p>在考虑 IGM Biosciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 IGM Biosciences 并不在名单上。</p>
<p>尽管 IGM Biosciences 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IGMS

<p>IGM Biosciences, Inc.（纳斯达克代码：IGMS）获得了十位分析师的共识评级为 “减持”，其中一位给予卖出评级，九位给予持有评级。平均一年期目标价为 5.50 美元。该股票开盘价为 1.27 美元，52 周区间为 0.92 美元至 22.50 美元。公司在上个季度报告的每股收益为 1.58 美元，超出预期。机构投资者持有该股票的 42.79%。IGM Biosciences 开发用于癌症和自身免疫疾病的 IgM 抗体</p>

<p>Shares of IGM Biosciences, Inc. (NASDAQ:IGMS - Get Free Report) have been assigned a consensus rating of &#34;Reduce&#34; from the ten analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and nine have given a hold rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $5.50.</p>
<div class="lb-trans"><p>IGM Biosciences, Inc.（纳斯达克代码：IGMS - 获取免费报告）的股票目前被十位分析师一致评定为 “减持”，MarketBeat Ratings 报告称。其中一位股票研究分析师给予该股票 “卖出” 评级，九位分析师则给予该公司 “持有” 评级。在过去一年中更新了对该股票覆盖的分析师中，平均一年目标价为 5.50 美元。</p>
</div><p>Get <strong>IGM Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>IGM Biosciences</strong> 的提醒：</p>
</div><p>Separately, Wall Street Zen lowered shares of IGM Biosciences from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, June 7th.</p>
<div class="lb-trans"><p>另外，华尔街禅在 6 月 7 日的报告中将 IGM Biosciences 的股票评级从 “持有” 下调至 “卖出”。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on IGM Biosciences</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 IGM Biosciences 股票分析</strong></p>
</div><h2>IGM Biosciences Stock Performance</h2>
<div class="lb-trans"><h2>IGM Biosciences 股票表现</h2>
</div><p>NASDAQ:IGMS opened at $1.27 on Thursday. IGM Biosciences has a 52 week low of $0.92 and a 52 week high of $22.50. The firm has a market cap of $76.57 million, a price-to-earnings ratio of -1.41 and a beta of 0.60. The firm's 50-day simple moving average is $1.27 and its 200 day simple moving average is $1.28.</p>
<div class="lb-trans"><p>纳斯达克：IGMS 周四开盘价为 1.27 美元。IGM Biosciences 的 52 周低点为 0.92 美元，52 周高点为 22.50 美元。该公司的市值为 7657 万美元，市盈率为-1.41，贝塔值为 0.60。该公司的 50 日简单移动平均线为 1.27 美元，200 日简单移动平均线为 1.28 美元。</p>
</div><p>IGM Biosciences (NASDAQ:IGMS - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The company reported $1.58 EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $1.88. IGM Biosciences had a negative return on equity of 93.35% and a negative net margin of 36.81%. The business had revenue of $143.62 million during the quarter, compared to the consensus estimate of $3.20 million. Sell-side analysts anticipate that IGM Biosciences will post -3.35 EPS for the current year.</p>
<div class="lb-trans"><p>IGM Biosciences（纳斯达克：IGMS - 获取免费报告）最近于 7 月 31 日发布了季度财报。该公司报告的季度每股收益为 1.58 美元，超出分析师一致预期的-0.30 美元，差额为 1.88 美元。IGM Biosciences 的股本回报率为-93.35%，净利润率为-36.81%。该公司在本季度的收入为 1.4362 亿美元，而一致预期为 320 万美元。卖方分析师预计 IGM Biosciences 在本年度将发布-3.35 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On IGM Biosciences</h2>
<div class="lb-trans"><h2>对 IGM Biosciences 的对冲基金看法</h2>
</div><p>Several hedge funds have recently bought and sold shares of IGMS. Sanofi bought a new stake in shares of IGM Biosciences during the 4th quarter valued at approximately $8,792,000. Two Sigma Investments LP grew its holdings in shares of IGM Biosciences by 196.7% during the 4th quarter. Two Sigma Investments LP now owns 107,620 shares of the company's stock valued at $658,000 after purchasing an additional 71,343 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of IGM Biosciences by 3.4% during the 4th quarter. Geode Capital Management LLC now owns 409,133 shares of the company's stock valued at $2,501,000 after purchasing an additional 13,334 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of IGM Biosciences by 14.0% during the 4th quarter. Renaissance Technologies LLC now owns 75,800 shares of the company's stock valued at $463,000 after purchasing an additional 9,300 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of IGM Biosciences during the 4th quarter valued at approximately $222,000. 42.79% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金最近买入和卖出了 IGMS 的股票。赛诺菲在第四季度新购入了 IGM Biosciences 的股份，价值约 879.2 万美元。Two Sigma Investments LP 在第四季度将其在 IGM Biosciences 的持股增加了 196.7%。Two Sigma Investments LP 目前拥有 107,620 股该公司的股票，价值 65.8 万美元，此前在上一季度又购买了 71,343 股。Geode Capital Management LLC 在第四季度将其在 IGM Biosciences 的持股增加了 3.4%。Geode Capital Management LLC 目前拥有 409,133 股该公司的股票，价值 250.1 万美元，此前在上一季度又购买了 13,334 股。Renaissance Technologies LLC 在第四季度将其在 IGM Biosciences 的持股增加了 14.0%。Renaissance Technologies LLC 目前拥有 75,800 股该公司的股票，价值 46.3 万美元，此前在上一季度又购买了 9,300 股。最后，Susquehanna Fundamental Investments LLC 在第四季度新购入了 IGM Biosciences 的股份，价值约 22.2 万美元。42.79% 的股票由机构投资者持有。</p>
</div><h2>About IGM Biosciences</h2>
<div class="lb-trans"><h2>关于 IGM Biosciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>IGM Biosciences, Inc, a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases.</p>
<div class="lb-trans"><p>IGM Biosciences, Inc.是一家临床阶段的生物技术公司，开发用于治疗癌症以及自身免疫和炎症性疾病的免疫球蛋白 M（IgM）抗体。它开发了 Aplitabart，一种用于治疗结直肠癌的死亡受体 5 激动剂 IgM 抗体；imvotamab，一种 CD20 x CD3 双特异性 IgM 抗体，用于治疗肌炎，以及用于治疗系统性红斑狼疮和类风湿性关节炎，目前处于 Ib 期临床试验；以及 IGM-2644，一种双特异性 T 细胞结合 IgM 抗体，靶向 CD38 和 CD3 蛋白，用于治疗自身免疫疾病。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than IGM Biosciences</li>
<li>Basic Materials Stocks Investing</li>
<li>3 Earnings Reports Give a Snapshot of Consumer Sentiment</li>
<li>Earnings Per Share Calculator: How to Calculate EPS</li>
<li>Amazon’s Bears Have Raised the White Flag—Get Excited</li>
<li>Stock Ratings and Recommendations: Understanding Analyst Ratings</li>
<li>Tempus AI’s Strong Q2 Fuels Growth Story—More Upside Ahead?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 IGM Biosciences 更好</li>
<li>基础材料股票投资</li>
<li>三份财报提供消费者情绪快照</li>
<li>每股收益计算器：如何计算 EPS</li>
<li>亚马逊的空头已举白旗——值得期待</li>
<li>股票评级和推荐：理解分析师评级</li>
<li>Tempus AI 强劲的第二季度推动增长故事——未来还有更多上升空间？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUdNUw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=IGMS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in IGM Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 IGM Biosciences 吗？</h2>
</div><p>Before you consider IGM Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 IGM Biosciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IGM Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 IGM Biosciences 并不在名单上。</p>
</div><p>While IGM Biosciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 IGM Biosciences 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

IGM Biosciences, Inc.（纳斯达克股票代码：IGMS）被分析师给予 “减持” 的平均评级